Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033718 | 0.82 | MAPT (0.43) | MAPTGAATP53SMN1; SMN2NPC1 | |
| SCHEMBL15033703 | 0.77 | MAPT (0.63) | MAPTTP53SMN1; SMN2RAPGEF4LMNA | |
| SCHEMBL15083664 | 0.76 | CCR2 (0.43) | MAPTGAATP53SMN1; SMN2RAPGEF4 | |
| SCHEMBL16257510 | 0.76 | RAPGEF4 (0.41) | MAPTTP53SMN1; SMN2RAPGEF4NPC1 | |
| SCHEMBL275004 | 0.68 | CYP1A2 (0.48) | MAPTGAASMN1; SMN2PDE10AMEN1 | |
| SCHEMBL17526195 | 0.68 | BRD4 (0.58) | MAPTGAANPC1RAB9APDGFRB | |
| SCHEMBL10956452 | 0.67 | ERBB2 (0.55) | TP53SMN1; SMN2RAPGEF4NPC1RAB9A | |
| SCHEMBL15119853 | 0.67 | NPC1 (0.43) | MAPTSMN1; SMN2NPC1RAB9ADYRK1A | |
| SCHEMBL15033751 | 0.67 | KMO (0.45) | MAPTSMN1; SMN2RAPGEF4NPC1RAB9A | |
| SCHEMBL9629953 | 0.66 | MAPT (0.65) | MAPTGAATP53SMN1; SMN2RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721025-B1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-8946218-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2569295-B1 | NEW CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | CCR2, CCRL2, CXCR2 | MAPT 4161/4885GAA 4851/4885TP53 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.